Table 4.

At least grade 3 AEs in patients with R/R TCL exposed to GBV induction phase and maintenance phase

AEInduction phase (N = 71)Maintenance phase (N = 28)
No. of patients% of patientsNo. of eventsNo. of patients% of patientsNo. of events
Total 58 81.7 189 11 39.3  
Neutropenia 39 54.9 74 21.4 
Thrombocytopenia 10 14.1 15 0.0 
Anemia 15 21.1 24 0.0 
Febrile neutropenia 3.1 0.0 
Infection 10  14.1 13 2  7.1 
Peripheral neuropathy 4.2 14.3 
Cardiovascular 7.0 0.0 
Gastrointestinal 5.6 0.0 
Liver 5.6 0.0  
Skin 4.2 3.6 
Ionogram abnormalities 2.8 0.0 
Respiratory 2.8 3.6 
Tumor lysis syndrome 1.7 0.0 
Lipase increased 1.7 0.0 
Arthritis 1.7 0.0 
Sudden death 1.7 0.0 
AEInduction phase (N = 71)Maintenance phase (N = 28)
No. of patients% of patientsNo. of eventsNo. of patients% of patientsNo. of events
Total 58 81.7 189 11 39.3  
Neutropenia 39 54.9 74 21.4 
Thrombocytopenia 10 14.1 15 0.0 
Anemia 15 21.1 24 0.0 
Febrile neutropenia 3.1 0.0 
Infection 10  14.1 13 2  7.1 
Peripheral neuropathy 4.2 14.3 
Cardiovascular 7.0 0.0 
Gastrointestinal 5.6 0.0 
Liver 5.6 0.0  
Skin 4.2 3.6 
Ionogram abnormalities 2.8 0.0 
Respiratory 2.8 3.6 
Tumor lysis syndrome 1.7 0.0 
Lipase increased 1.7 0.0 
Arthritis 1.7 0.0 
Sudden death 1.7 0.0 

Including Pneumonia (n = 3), sepsis or septic shock (n = 3), Campylobacter infection (n = 1), Clostridium difficile colitis (n = 1), device-related infection (n = 1), Pneumocystis jirovecii pneumonia (n = 1), and Pseudomonas infection (n = 1).

Including bronchitis (n = 1) and cytomegalovirus chorioretinitis (n = 1).

or Create an Account

Close Modal
Close Modal